PSA nadir after 125I prostate brachytherapy

Atsunori Yorozu, K. Toya, K. Yoshida, N. Koike, A. Takahashi, S. Saito, T. Nishiyama, Y. Yagi, R. Namitome, A. Ashikari, T. Kono

Research output: Contribution to journalArticlepeer-review


To evaluate the prostate-specific antigen (PSA) kinetics and nadir of PSA failure after permanent 125I prostate brachytherapy. The study included 660 patients with a potential minimum follow-up of 5 years. Patients who met the Phoenix definition of PSA failure were identified. The PSA decreased gradually to less than 0.2ng/mL even after 5 years for many patients. The median PSA nadir was 0.09ng/mL. Neoadjuvant hormone therapy had little effect on PSA nadir. The PSA nadir < = 0.2ng/mL or current nadir < = 0.4ng/mL seemed to be a good marker as a successful treatment.

Original languageEnglish
Pages (from-to)793-796
Number of pages4
JournalJapanese Journal of Clinical Radiology
Issue number6
Publication statusPublished - 2012 Jun 10
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'PSA nadir after 125I prostate brachytherapy'. Together they form a unique fingerprint.

Cite this